Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Immunoregulatory Dendritic Cells in Type 1 Diabetes
NCT02354911Phase 2Withdrawn
- Sponsor
- DiaVacs, Inc.
- Start
- Oct 2015
- Primary completion
- Feb 2024
- Modality
- Whole Cell Cancer Vaccines, Modified DNA Oligonucleotides, Single-strand DNA
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing DV-0100 First with Placebo First (2 arms). Primary endpoint: Change from baseline in the mean 2-hour area under the curve (AUC) for plasma c-peptide at 24 months. Planned start Oct 2015; status: withdrawn.
02
Drugs
diabetes-suppressive dendritic cell vaccine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02354911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354911.